PD-L1 expression

Finally, competitive experiments in the presence of durvalumab are also described to study its interaction with PD-L1. This approach can also be used to study the contribution of potential conformational changes in other proteins.

Four of the seven drugs (57%) were recommended as highly or moderately preferred treatment options in Japanese guidelines: gemtuzumab ozogamicin for acute myeloid leukemia, gefitinib for EGFR-positive non-small cell lung cancer, bevacizumab for HER2-negative metastatic breast cancer, and atezolizumab with nab-paclitaxel for PD-L1-positive triple-negative breast cancer. Despite regulatory withdrawal in the US due to unproven clinical benefits, drugs retained in Japan received positive guideline recommendations. This finding highlights regional variations in regulatory decisions and different approaches to benefit-risk assessments, suggesting a need for improved transparency in Japan's regulatory decisions and guideline recommendations, with clearer justifications for endorsing drugs that are considered to have unproven clinical benefits in the US.

Compared with systemic ICB, local immunotherapy with EmDEX@GA has better therapeutic efficacy on suppressing distant metastasis. Moreover, the study suggests that the occurrences of distant metastasis are associated with the immunosuppressive microenvironment rather than the metastasis in TDLNs, indicating that targeted immunomodulation of TDLNs is necessary.

Fractionated radiation (5 Gy × 3) further amplified PD-L1 upregulation (13.9% ± 1.54% ID/cc) compared with a single dose (11.48% ± 1.05% ID/cc). Taken together, [18F]AlF-NOTA-PCP2 may be a valuable tool for noninvasively monitoring PD-L1 expression in brain tumors after radiotherapy.

It reshapes the immune microenvironment by increasing immune infiltration and changing the fraction of immune cells. In tumor immune microenvironment, CXCR2P1 can promote inflammation, enhance antigen presentation and activate the PD-1/PD-L1-related signaling pathway, which might be achieved by CXCR2P1-MIR215 axis.

P1, N=1274, Active, not recruiting, Exelixis | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Jun 2030 | Trial primary completion date: Feb 2026 --> Jun 2030

P3, N=700, Not yet recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital

P2, N=58, Completed, Beijing Cancer Hospital; Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd

P2, N=30, Not yet recruiting, West China Hospital , Sichuan University; West China Hospital , Sichuan University

Most patients received pembrolizumab (93%) and were treated with stereotactic radiation (81%)...Although high PD-L1 levels are associated with longer survival and improved intracranial control, radiation necrosis occurs more frequently in patients with high PD-L1 expression. Clinicians should be aware of long-term treatment-related toxicities in this population.

P2, N=16, Active, not recruiting, Andrew Hendifar, MD | Trial completion date: Feb 2025 --> Feb 2026

P=N/A, N=312, Not yet recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci

In addition, we found that ETS1 promotes PLA2G7 overexpression in bladder cancer cells. In summary, our findings provide a novel immunotherapeutic strategy against bladder cancer through targeting the ETS1-PLA2G7-STAT1/STAT3-PD-L1 axis.

CMMS detection has significant utility in the prognosis of patients at an early stage and identification of potential candidates for immunotherapy.

Nivolumab in the adjuvant setting is likely to be cost-effective compared to surveillance in France.

GC plus immunotherapy is still the standard of care for late stage BTC. PD-L1 expression and TMB were not good predictors for selecting patients who would benefit more from immunotherapy plus chemotherapy.

Initially, PD-1 and PDL-1 were higher in patients than in controls and decreased 6 months after treatment. PD-1 and PDL-1 expression was associated with increased remission rates, implicating that modulation of PD-1 and PDL-1 expression may be a therapeutic approach for B-ALL. Moreover, this study created a new method for the assessment of PD-1 and PDL-1 in B-ALL.

While both DM and CLE showed strong interferon signatures, DM uniquely displayed IFN-β expression. Together, our study provides the first comprehensive spatial mapping of immune and stromal cells in adult-onset DM.

Based on our preliminary results, TMB and PD-L1 can serve as potential early screening clinical biomarkers and molecular targets for immune treatment in ESCC. However, there is no apparent statistical association between TMB and PD-L1 expression levels. Furthermore, PD-L1 and TMB may independently influence the efficacy of immunotherapy, highlighting the inadequacy of single-marker detection in effectively predicting treatment outcomes.

P1, N=15, Recruiting, Emory University | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2026

P2, N=185, Completed, Intergroupe Francophone de Cancerologie Thoracique | Active, not recruiting --> Completed

Methylation of SHOX2 and RASSF1A serves as a valuable diagnostic biomarker for MPE, providing an adjunct to cytological diagnosis.

Patients with COPD were at increased risk of developing autoimmune thyroiditis compared to non-COPD patients (OR 3.9 95% CI 1.135-13.260, p = 0.0227). Our study showed that patients dealing with COPD have a 3.9 times greater risk of developing autoimmune thyroiditis as an adverse event during Pembrolizumab treatment compared with patients without COPD.

The above results were verified in all six cell lines. The present study suggested that increased Sirt6 expression and activity in tumor cells can suppress immune surveillance by increasing Treg, ADO, PD-1 and PD-L1 levels, decreasing IFN-γ production, and altering tumor-promoting and antitumor gene expression in the microenvironment.

Both the primary lung and metastatic liver lesion showed a tendency to shrink. This regimen may be considered a promising treatment for non-small cell lung carcinoma resembling hepatoid carcinoma as it achieved survival beyond the previously reported median.

Poor survival with PD-L1 positivity is likely reflective of the increased aggressiveness conferred by the PD-L1-induced immune evasion. PD-L1, a negative predictive biomarker, may serve as a novel target in immunotherapy for gliomas.

In comparison to traditional immune checkpoint inhibitors, NK-exo possessed unique mechanisms of action and potential advantages. NK-exo holds the promise of becoming an innovative immunotherapy for the treatment of LC.

Additionally, RNF220 promoted PD-L1 expression by destabilizing PDE10A, thereby facilitating immune evasion in BCa. These findings establish RNF220 as a pivotal ubiquitinase that drives both cisplatin resistance and immune escape through PDE10A destabilization, highlighting its potential as a therapeutic target to enhance chemotherapy and immunotherapy efficacy in advanced BCa.

P3, N=1264, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Dec 2026 --> Sep 2024

Both Acteoside and Plantamajoside have demonstrated promising anticancer properties by inhibiting the growth and metastasis of MCF-7 cancer cell line. These compounds induce apoptosis, modulate the PD-1 checkpoint pathway, and influence PD-L1 expression, which may indicate possible molecular mechanisms for their anticancer effects.

The expression of immune checkpoints including PD-L1 in naive tumors does not reflect those in recurrent tumors. Increasing PD-L1 expression in immune cells may cause early recurrence of HNSCC.

NACRT in pancreatic cancer may affect TILs and PD-L1 expression, thereby improving the immunosuppressive microenvironment and implying a potential synergy between checkpoint inhibitors and radiation treatment.

The incidence of thyroid dysfunction was significantly higher in patients treated with atezolizumab compared to pembrolizumab (P = 0.04), with 87.5% of affected patients receiving atezolizumab. These findings suggest that thyroid dysfunction is a common irAE in patients with metastatic NSCLC receiving ICIs, particularly atezolizumab, and its development may be associated with improved PFS. Regular monitoring of thyroid function is recommended to promptly identify and manage thyroid abnormalities during ICI therapy, potentially improving patient outcomes.

We elucidated the molecular mechanisms underlying the simultaneous occurrence of ferroptosis resistance and immune suppression in PDAC patients. Our study provides a novel therapeutic strategy that could promote ferroptosis in tumour cells and increase immunotherapy efficacy.

No abstract available

No abstract available

P2, N=189, Active, not recruiting, ALX Oncology Inc. | Trial primary completion date: Dec 2024 --> Jun 2025

Pembrolizumab together with chemotherapy improves greater survival and higher levels of response rate in patients with severe gastric cancer, especially with high PD-L1 expression. But it has rather more adverse events, allowing patient monitoring with care.

The use of monoclonal antibodies on B cells plays a critical role in the B cell function through the reduction in CD38 expressing activated B cells and upregulation of CD19+CD27+ B cells. Moreover, the monoclonal antibody targeting PD-1, PD-L1 and CTLA-4 are effective in reducing the expression of CTLA-4 on B cell subsets, while PD-1 and PD-L1 blockage may be effective in reducing the expression of these immune checkpoints on total B cells.

This study highlights the significance of PDCD1 nsSNPs as potential biomarkers for cancer susceptibility, advancing the understanding of PD-1 regulation. Experimental validation and multi-omics integration are crucial to refine these findings and enhance theraputic strategies.

Transfection of mes-miR395e mimics into RCC-derived cell lines confirmed that this miRNA decreases expression of PD-L1 in RCC cells at both mRNA and protein levels. This preliminary study shows the promise of plant miRNA as potential adjuvants supporting RCC treatment.

CD73 expression in EGFRm LUAD is heterogeneous and associated with diverse TME profiles. These findings support the potential of CD73 as a predictive biomarker and therapeutic target, highlighting its clinical relevance in EGFRm LUAD.